TechBio Boost

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 million seed funding round.

LinkGevity featured in Financial Times 5-part global series on Longevity companies. The article highlights how LinkGevity’s pioneering work on Anti-Necrotic technology is opening new frontiers in medicine, with potential for systemic healthspan regeneration.

Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.' 

Since joining the TechBio Boost programme, SokerData has refined its business model, adopted a more strategic approach to market entry, built new partnerships and is securing funding to accelerate R&D and commercialisation.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, discusses the recent Techbio Boost event hosted by KQ Labs and the BIA, highlighting the programme's role in supporting the growth of London-based techbio seed and pre-series A companies.

Attending the BIA’s TechBio UK conference this year offered an incredible opportunity to witness the ingenuity and innovation driving the future of life sciences.

New legislation was laid in Parliament last Thursday to modernise the regulation of clinical trials in the UK.

​​​​​​​LinkGevity and Delta Biosciences, UAB, a Lithuanian pharmaceutical stability specialist, have been awarded funding from the UK Space Agency to prepare LinkGevity’s pioneering Anti-Necrotic therapeutic for deployment in space.

LinkGevity has been selected to receive a highly competitive Women TechEU grant. This prestigious award, funded by Horizon Europe, highlights the groundbreaking nature of LinkGevity's work and positions the company among Europe's most promising deep tech startups.

LinkGevity, an AI-driven drug discovery company focused on longevity and age-related disease, announces its selection for the highly competitive SPACE-H Accelerator program, powered by Starburst in collaboration with NASA’s Human Research Program (NASA HRP), the Translational Research Institute for Space Health (TRISH), and Microsoft Federal (Microsoft).

In a new report, Concr team describe a ‘critical imbalance’ in a research and funding landscape where ‘other’ cancers are left in the dark.

New partnership will drive precision therapy leveraging diverse data from the Caribbean population

The Francis Crick Institute’s start-up accelerator KQ Labs and the UK Bioindustry Association (BIA) have launched a new programme to support growing companies working at the interface of biology and data technologies.